P A Foster

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer
    Paul A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Anticancer Res 28:577-81. 2008
  2. ncbi request reprint In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy
    Paul A Foster
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College Faculty of Medicine, St Mary s Hospital, London, United Kingdom
    Clin Cancer Res 12:5543-9. 2006
  3. ncbi request reprint STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells
    Paul A Foster
    Oncology Drug Discovery and Women s Health Group, Faculty of Medicine, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Anticancer Res 29:3751-7. 2009
  4. ncbi request reprint Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer
    Paul A Foster
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College Faculty of Medicine, St Mary s Hospital, London, W2 1NY, UK
    Breast Cancer Res Treat 111:129-38. 2008
  5. ncbi request reprint 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique
    Paul A Foster
    Faculty of Medicine, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Breast Cancer Res Treat 111:251-60. 2008
  6. ncbi request reprint Recent developments of steroid sulfatase inhibitors as anti-cancer agents
    Paul A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Anticancer Agents Med Chem 8:732-8. 2008
  7. ncbi request reprint A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor
    Paul A Foster
    Faculty of Medicine, Imperial College London, UK
    Clin Cancer Res 14:6469-77. 2008
  8. pmc The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer
    Paul A Foster
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, United Kingdom
    Endocrinology 149:4035-42. 2008
  9. ncbi request reprint Steroid metabolism in breast cancer
    P A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Minerva Endocrinol 33:27-37. 2008
  10. pmc BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
    J M Day
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 100:476-86. 2009

Collaborators

Detail Information

Publications23

  1. ncbi request reprint A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer
    Paul A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Anticancer Res 28:577-81. 2008
    ..A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated...
  2. ncbi request reprint In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy
    Paul A Foster
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College Faculty of Medicine, St Mary s Hospital, London, United Kingdom
    Clin Cancer Res 12:5543-9. 2006
    ..We compare the in vivo efficacy of two potent STS inhibitors, STX64 and STX213, in a xenograft breast cancer model...
  3. ncbi request reprint STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells
    Paul A Foster
    Oncology Drug Discovery and Women s Health Group, Faculty of Medicine, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Anticancer Res 29:3751-7. 2009
    ..This work details the temporal organisation of apoptosis induced by two microtubule disruptors and highlights the role that the down-regulation of survivin and XIAP may play in this process...
  4. ncbi request reprint Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer
    Paul A Foster
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College Faculty of Medicine, St Mary s Hospital, London, W2 1NY, UK
    Breast Cancer Res Treat 111:129-38. 2008
    ..This study indicates that the STS inhibitor, STX213, exhibits excellent efficacy and pharmacokinetics and therefore offers a potentially novel treatment for hormone-dependent breast cancer...
  5. ncbi request reprint 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique
    Paul A Foster
    Faculty of Medicine, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Breast Cancer Res Treat 111:251-60. 2008
    ..As these compounds are anti-proliferative against breast cancer and endothelial cells they have the potential to be potent, dual acting clinical drugs of the future...
  6. ncbi request reprint Recent developments of steroid sulfatase inhibitors as anti-cancer agents
    Paul A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Anticancer Agents Med Chem 8:732-8. 2008
    ..However, there are other hormone-dependent malignancies, such as endometrial and prostate cancer, that could in the future be treated with these new potent STS inhibitors...
  7. ncbi request reprint A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor
    Paul A Foster
    Faculty of Medicine, Imperial College London, UK
    Clin Cancer Res 14:6469-77. 2008
    ..Both these enzymes play a critical role in the formation of estrogenic steroids and their inhibitors are now showing success in the clinic...
  8. pmc The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer
    Paul A Foster
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, United Kingdom
    Endocrinology 149:4035-42. 2008
    ..This novel study demonstrates for the first time that STS inhibitors are potent inhibitors of endometrial cancer growth in nude mice...
  9. ncbi request reprint Steroid metabolism in breast cancer
    P A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London, W2 1NY, UK
    Minerva Endocrinol 33:27-37. 2008
    ..However, such endocrine therapy that is currently being explored has shown promising results for patients with hormone-dependent breast cancer...
  10. pmc BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
    J M Day
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 100:476-86. 2009
    ..This is despite an increase in BCRP expression in A2780 cells in vitro after chronic dosing with STX140...
  11. pmc The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer
    M F C Parsons
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 99:1433-41. 2008
    ..These results show that STX243 is a potent in vivo drug and could be clinically effective at treating a number of oncological conditions...
  12. pmc 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
    S L C Tagg
    Oncology Drug Discovery and Women s Health Group, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 99:1842-8. 2008
    ..This is the first study to show the benefit of combining a microtubule disruptor with 2DG in the two most common solid tumours...
  13. pmc The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
    S P Newman
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 97:1673-82. 2007
    ..In contrast to the taxanes, STX140 can be dosed orally, with no toxicity being observed even after prolonged daily dosing...
  14. ncbi request reprint A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140
    Paul A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Anticancer Res 28:1483-91. 2008
    ..This study characterises two recently developed anticancer agents in vitro and in vivo, 2-methoxyoestra-1,3,5(10), 16-tetraene-3-carboxamide (IRC-110160) and STX140...
  15. ncbi request reprint The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy
    Joanna M Day
    Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London, W2 1NY, United Kingdom
    Ann N Y Acad Sci 1155:80-7. 2009
    ..Results from these investigations therefore suggest that STS inhibitors could have therapeutic potential for the treatment of a range of hormone-dependent cancers...
  16. pmc In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
    C Stengel
    1 Oncology Drug Discovery Group, Section of Investigative Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK 2 Cancer Institute, UCL, 72 Huntley Street, London WC1E 6BT, UK
    Br J Cancer 111:300-8. 2014
    ..Crucially, STX2484 has superior efficacy to paclitaxel in models of clinical drug resistance. ..
  17. pmc In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
    S K Chander
    Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 96:1368-76. 2007
    ..This, together with their ability to inhibit tumour growth, indicates the potential of this new class of drugs for further development for cancer therapy...
  18. ncbi request reprint Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3
    Joanna M Day
    Oncology Drug Discovery and Women s Health Group, Department of Endocrinology and Metabolic Medicine, and Sterix Ltd, Imperial College London, London W2 1NY, UK
    Mol Cell Endocrinol 301:251-8. 2009
    ..Active compounds are selective for 17beta-HSD3 over 17beta-HSD1 and 17beta-HSD2, non-androgenic with low toxicity, and efficacious in both an in vitro proof of concept model and in an in vivo tumour model...
  19. ncbi request reprint STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells
    Simon P Newman
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St Mary s Hospital, London, UK
    Clin Cancer Res 14:597-606. 2008
    ..In addition, its efficacy was determined against xenografts derived from patients who failed docetaxel therapy...
  20. ncbi request reprint 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer
    Joanna M Day
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London W2 1NY, United Kingdom
    Int J Cancer 122:1931-40. 2008
    ..Both E2 production and tumor growth were inhibited by STX1040, suggesting that 17beta-HSD1 inhibitors such as STX1040 may provide a novel treatment for hormone-dependent breast cancer...
  21. ncbi request reprint Cellular pathology changes in rat skin following intradermal injection of nerve growth factor: neutrophil-dependent and -independent events
    Paul A Foster
    Centre for Cardiovascular Biology and Medicine, King s College, London, UK
    J Pathol 197:245-55. 2002
    ..The results also suggest that NGF can have a profound effect on rat muscle and that this effect may be related to muscle regeneration...
  22. ncbi request reprint Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
    L W Lawrence Woo
    Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd, University of Bath, Claverton Down, Bath, United Kingdom
    Mol Cancer Ther 7:2435-44. 2008
    ..Compound (10) and other related inhibitors of this structural class further expand the armory of steroid sulfatase inhibitors against hormone-dependent breast cancer...
  23. doi request reprint Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents
    Mathew P Leese
    Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
    J Med Chem 51:1295-308. 2008
    ..The potential of these multimechanism anticancer agents was confirmed in vivo, with promising activity observed for both 14 and 15 in an athymic nude mouse MDA-MB-231 human breast cancer xenograft model...